Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Bayer and Recursion focus research collaboration on oncology
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.
Bayer expands global life science incubator network
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
This move establishes new sites for the Bayer Co.Lab program at the hotspots of innovation in China as well as in Japan.
Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
More Pharma News ...
- Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
- Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
- AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
- FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
- CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
- Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.